ARTICLE | Clinical News
Thalomid thalidomide: Phase II data; marketed to treat erythema nodosum leprosum in leprosy
November 8, 1999 8:00 AM UTC
National Cancer Institute researchers presented data from 63 androgen independent prostate cancer patients in which 53 and 68 percent of low and high dose Thalomid patients, respectively, had declines...